Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters

Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters

Abstract With the persistence of the SARS-CoV-2 pandemic and the emergence of novel variants, the development of novel vaccine formulations with enhanced immunogenicity profiles could help reduce disease burden in the future. Intranasally delivered vaccines offer a new modality to prevent SARS-CoV-2...

Full description

Bibliographic Details
Main Authors: Felicity C. Stark, Bassel Akache, Lise Deschatelets, Anh Tran, Matthew Stuible, Yves Durocher, Michael J. McCluskie, Gerard Agbayani, Renu Dudani, Blair A. Harrison, Tyler M. Renner, Shawn R. Makinen, Jegarubee Bavananthasivam, Diana Duque, Martin Gagne, Joseph Zimmermann, C. David Zarley, Terrence R. Cochrane, Martin Handfield
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-13819-5

Internet

https://doi.org/10.1038/s41598-022-13819-5

Similar Items